Rezolute's Rare Disease Drug Fails to Beat Placebo in Key Trial
Rezolute's ersodetug therapy for congenital hyperinsulinism failed Phase 3 trial, missing primary endpoints. Stock plunged 90% as the drug showed no significant advantage over placebo.
NOTRELOAD AI
BofA Cuts PayPal Rating as Growth Reboot Slows
Bank of America downgraded PayPal to Neutral, lowering its price target to $68. The firm cites slower-than-expected progress in boosting branded checkout growth and expects limited near-term upside.
Arista Networks Earns Continued Buy Rating from Evercore ISI
Evercore ISI reiterates a Buy rating on Arista Networks with a $175 price target, citing strong revenue growth, impressive margins, and long-term sector positioning.
Quantum Computing Stocks Gain Momentum After New Analyst Ratings
Analysts boost outlook for IonQ, Rigetti, and D-Wave as quantum computing demand grows, with major industry expansion expected by 2040.
Eli Lilly's Groundbreaking Obesity Drug Shows Record-Breaking Weight Loss Results
Eli Lilly's experimental retatrutide helps patients lose up to 24% body weight in trials, setting new standards for obesity treatment but with notable side effects and dropout rates.
Unity Stock Gets Double Upgrade Boost as Ad Business Gains Momentum
Unity receives upgrades from BTIG and Piper Sandler, citing stronger ad performance, industry tailwinds, and underappreciated growth levers. Analysts raise price targets to $59–$60.